cmAngio® vs Eko Analysis Software
AI Verdict
Choose cmAngio® if…
Choose cmAngio® if your practice seeks to leverage existing mammography screenings for proactive cardiovascular risk assessment in women. This tool is ideal for identifying Breast Arterial Calcifications (BAC) to provide early insights into cardiovascular health without requiring additional patient procedures or radiation exposure.
View cmAngio® →Choose Eko Analysis Software if…
Choose Eko Analysis Software if your clinical workflow involves real-time auscultation and ECG analysis for the early detection of cardiovascular diseases like heart murmurs and atrial fibrillation. This software is best suited for clinicians using digital stethoscopes who need immediate AI-powered insights during patient encounters or for remote monitoring and telehealth applications.
View Eko Analysis Software →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | cmAngio® | Eko Analysis Software |
|---|---|---|
| Pricing | Paid, out-of-pocket | Freemium with subscription for full features |
| Deployment | Cloud-based, integrates with any DICOM-compliant viewer | Cloud-based |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
cmAngio®cmAngiou00ae emphasizes seamless integration into existing radiology workflows with quick installation and compatibility with any DICOM viewer, minimizing disruption. Eko Analysis Software, while user-friendly with its mobile app, requires specific Eko hardware, which could be an additional barrier to adoption for some users.
Clinical Value
cmAngio®Both tools offer significant clinical value through FDA-cleared AI for early disease detection. However, cmAngiou00ae uniquely leverages existing mammography data to provide novel insights into cardiovascular risk (BAC), adding value without requiring new procedures or patient burden. This repurposing of routine imaging data for a secondary, critical health assessment provides a distinct advantage.
Pricing & Value
Eko Analysis SoftwareEko Analysis Software offers a transparent freemium model, allowing users to evaluate basic features before committing to a subscription for full AI capabilities. In contrast, cmAngiou00ae's pricing is not publicly available and requires direct contact, which can be a barrier to initial assessment of value.
Enterprise Readiness
Eko Analysis SoftwareBoth tools are FDA-cleared, HIPAA-compliant, and cloud-based. However, Eko Analysis Software explicitly states it has a Business Associate Agreement (BAA) available, which is crucial for enterprise deployments. cmAngiou00ae requires contacting the vendor for BAA details, indicating less immediate transparency for enterprise legal and compliance teams.
Innovation
cmAngio®cmAngiou00ae demonstrates higher innovation by repurposing existing mammography data to identify a novel cardiovascular risk factor (BAC), providing new diagnostic value without additional patient procedures. While Eko enhances traditional auscultation with AI, cmAngiou00ae's approach unlocks a new diagnostic pathway from an already routine screening.
Support & Docs
Eko Analysis SoftwareEko Analysis Software provides a robust and easily accessible Eko Help Center with detailed user manuals, troubleshooting guides, and direct support contact options. In contrast, cmAngiou00ae's documentation appears less transparent and readily available, with only a general mention of an 'Operator's Manual' in its product information.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | cmAngio® | Eko Analysis Software |
|---|---|---|
| Name | cmAngiou00ae | Eko Analysis Software |
| Company | CureMetrix | Eko Devices |
| Description | FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. | FDA-cleared AI-powered tool that integrates with Eko's digital stethoscopes and mobile app to assist clinicians in the early detection of cardiovascular diseases like heart murmurs and atrial fibrillation. |
| Primary AI Detection Focus | Breast Arterial Calcifications (BAC) | Heart murmurs and Atrial Fibrillation (AFib) |
| Key Features (Example) | AI-based detection of Breast Arterial Calcifications (BAC); Processes both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams. | FDA-cleared AI for heart murmur detection; FDA-cleared AI for atrial fibrillation (AFib) detection. |
Videos
Demos, reviews, and walkthroughs featuring cmAngio® and Eko Analysis Software.
Frequently Asked Questions
More Comparisons
More matchups featuring cmAngio® or Eko Analysis Software
Backers
Who funded each tool's parent company.